A study to evaluate the efficacy and safety of Tolvaptan and Carperitide in HF patients

A study to evaluate the efficacy and safety of Tolvaptan and Carperitide in HF patients - A study to evaluate the efficacy and safety of Tolvaptan and Carperitide in HF patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008257

Enrollment

Registered

2012-07-01

Start date

2012-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congestive heart failure

Interventions

tolvaptan 7.5-15mg/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) inpatients due to acute heart failure (2) patients with lack of efficacy regardless of carperitide 0.0125ug/min (or 0.025ug/min) (3) ability of oral administration (4) male or female who are over 20 years old at the time of informed consent (5) ability to provide written informed consent

Exclusion criteria

Exclusion criteria: (1) history of allergy against this drug or similar compounds (2) anuric patients (3) patients who cannot feel thirsty or have difficulty to drink (4) hypernatremia patients (5) patients who are pregnant or possibly pregnant (6) patients who already have tolvaptan at entry (7) acute myocardial infarction patients or planned revascularization during study period (8) patiets who administer intravenous diuretics except carperitide (9) patients who are judged to be inappropriate to this study

Design outcomes

Primary

Measure	Time frame
change in urine volume	—

Secondary

Measure	Time frame
Congestive symptoms, renal function, neurohumoral factors, safety and cardiovascular events	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026